sonelokimab
Sponsor Moonlake Immunotherapeutics · listed as MLTX
sonelokimab is a drug asset sponsored by Moonlake Immunotherapeutics, listed as MLTX. CSA tracks 3 forward catalysts for it — the nearest is a readout expected Jan 15, 2027 (day precision, medium confidence), tied to trial NCT06641089. That trial is in Phase 3 and currently recruiting, studying Arthritis, Psoriatic. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for sonelokimab
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-01-15 | READOUT | medium | NCT06641089 |
| 2027-02-04 | READOUT | medium | NCT06641076 |
| 2028-02-04 | READOUT | medium | NCT07223138 |
Trials for sonelokimab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06768671 | Phase 3 | Active, not recruiting | 2026-09-28 | Experimental | MoonLake Immunotherapeutics AG | Hidradenitis Suppurativa |
| NCT06641089 catalyst | Phase 3 | Recruiting | 2027-01-15 | Experimental | MoonLake Immunotherapeutics AG | Arthritis, Psoriatic |
| NCT06641076 catalyst | Phase 3 | Active, not recruiting | 2027-02-04 | Experimental | MoonLake Immunotherapeutics AG | Arthritis, Psoriatic |
| NCT07223138 catalyst | Phase 3 | Enrolling by invitation | 2028-02-04 | Experimental | MoonLake Immunotherapeutics AG | Arthritis, Psoriatic |
| NCT07007637 | Phase 3 | Enrolling by invitation | 2028-06-13 | Experimental | MoonLake Immunotherapeutics AG | Hidradenitis Suppurativa |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More MLTX catalysts